Antihistamine shows promise for MS eye disorder in Early-Ended trial
NCT ID NCT05338450
First seen May 11, 2026 · Last updated May 14, 2026 · Updated 2 times
Summary
This study tested whether clemastine fumarate, an antihistamine, could improve eye movement in people with multiple sclerosis (MS) who have a specific eye coordination problem called internuclear ophthalmoparesis (INO). The trial planned to enroll 80 adults with MS and INO, giving half clemastine and half a placebo for 6 months, then following them for 30 more months. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amsterdam UMC, location VUmc
Amsterdam, 1081 HV, Netherlands
Conditions
Explore the condition pages connected to this study.